Health Canada Approves First Generic Ozempic, Making Country First in G7 to Clear Cheaper Semaglutide

Health Canada on Tuesday approved the first generic version of semaglutide, the active ingredient in Novo Nordisk's blockbuster diabetes and weight loss drug Ozempic, making Canada the first country in the G7 to authorise a generic for the medication. The approval, granted to India-based Dr. Reddy's Laboratories, is expected to gradually lower the cost of one of the most prescribed and most expensive prescription medications in the country.

What was approved

Health Canada confirmed in a statement that it had assigned drug identification numbers to a generic semaglutide injection manufactured by Dr. Reddy's Laboratories Ltd. The approval covers the same indications as the brand-name product, including the management of type 2 diabetes and the cardiovascular and weight-loss indications for which Ozempic and Wegovy have become globally familiar names.

Novo Nordisk's patent protection on semaglutide expired in Canada on January 4, opening the door for generic manufacturers to seek approval. Health Canada said it currently has eight other applications for generic semaglutide products under review and expects to make additional decisions in the coming weeks and months as further bioequivalence and manufacturing dossiers clear regulatory checks.

The first generic medication in the Canadian market typically launches at 75 to 85 per cent of the brand-name price under the rules of the pan-Canadian Pharmaceutical Alliance. Once a second generic enters the market, the price for both falls to 50 per cent. With three or more generic options available, the price ratchets down to roughly 35 per cent of the brand-name product. That tiered framework means the most significant cost relief for Canadians will arrive only as additional manufacturers receive approval.

The context

Ozempic and its higher-dose sibling Wegovy have transformed the treatment landscape for type 2 diabetes and obesity since their introduction. The drug works by mimicking glucagon-like peptide-1, a hormone that helps regulate blood sugar and appetite. Demand has been so strong that supply shortages have repeatedly disrupted the market in Canada and globally.

The high price of brand-name Ozempic, often quoted at upwards of $300 per month, has been a recurring source of friction for patients, provincial drug plans and private insurers. Provinces have negotiated confidential rebates with Novo Nordisk, but the listed prices remain among the highest of any chronic-condition medication on Canadian shelves.

Health Canada's authorisation for Dr. Reddy's product comes ahead of similar decisions in the United States and Europe, where regulatory and patent timelines are different. Canadian regulators have framed the approval as a milestone for affordability and as evidence that the country's generic drug pathway can produce timely outcomes when patent and manufacturing conditions allow.

What it means for patients

For Canadians currently filling Ozempic prescriptions, the generic launch will not deliver immediate dramatic price relief. The first-to-market generic from Dr. Reddy's will arrive at a price still close to the brand-name version, although it will sit below the listed price. As additional generics receive approval, the price decreases will compound under the existing pharmaceutical alliance rules.

Patients on private insurance plans should see lower co-payments over time, depending on the plan's substitution rules. Provincial drug formularies will need to update their listings, and pharmacists will have discretion in many provinces to substitute the generic for the brand-name product unless the prescribing physician indicates otherwise.

For provincial drug plans, the savings could be substantial. Quebec, Ontario and British Columbia, which together cover the majority of Canadian public drug plan beneficiaries, are likely to see total program spending on semaglutide fall as generic uptake accelerates.

Industry reaction

The generic pharmaceutical industry, represented in Canada by the Canadian Generic Pharmaceutical Association, welcomed the approval as confirmation that Canadian regulatory pathways are working efficiently. Several Canadian generic manufacturers, including Toronto-based Apotex, are pursuing their own semaglutide applications and are expected to enter the market over the coming months as approvals are granted.

Novo Nordisk, the Danish company that developed Ozempic and Wegovy, did not contest the patent expiry in Canada and has indicated it will continue selling the brand-name product. The company has also been investing heavily in next-generation GLP-1 medications and combination therapies, as well as oral formulations that could shift the competitive landscape again in coming years.

Pharmacy chains have signalled they will support generic substitution where permitted, while patient advocacy groups have called for transparency around prices and clear communication to Canadians about what to expect at the counter as the market evolves.

Reaction from health policymakers

Health Minister Marjorie Michel called the approval a significant moment for affordability, noting that Canadians use generic medications routinely as a way to control out-of-pocket costs. She also highlighted the speed at which Canada has acted compared to other G7 peers, although the timing reflects in part the way patent litigation has played out in different jurisdictions.

Provincial health ministers have indicated they will move quickly to incorporate the generic onto provincial formularies. Several have also pressed for an updated national assessment of GLP-1 medications, given their growing use in obesity treatment beyond their original diabetes indication.

Equity and access concerns

Despite the milestone, equity advocates noted that the higher cost of weight-loss indications for semaglutide remains a barrier for many Canadians. While the diabetes indication is widely covered by public and private plans, coverage for obesity-related use remains patchy and varies sharply between provinces and insurance plans.

Indigenous health organisations also flagged the importance of improving access to GLP-1 medications in remote and northern communities, where rates of type 2 diabetes are significantly higher than the national average and where pharmacy supply chains can be more fragile.

Implications for the broader GLP-1 market

The approval comes at a moment when GLP-1 receptor agonist medications have become a focal point of global pharmaceutical innovation. Beyond Ozempic and Wegovy, drugmakers including Eli Lilly have advanced their own products for diabetes and weight loss, and several companies are working on next-generation oral formulations that could expand the patient population further.

For Canadian regulators, the cascade of new products and indications has created a complex environment for evaluating cost effectiveness. The Canadian Drug Agency, formerly known as the Canadian Agency for Drugs and Technologies in Health, has been studying the long-term implications of widespread GLP-1 use, particularly for cardiovascular outcomes and obesity-related complications such as sleep apnea and certain cancers.

Some health policy analysts argue that as generic prices drop further over the coming years, the case for broader public reimbursement of GLP-1 medications for obesity indications will strengthen significantly. Others caution that even at lower prices, the population eligible for these medications is large enough that public plans will need careful management to maintain financial sustainability.

What's next

Pharmacies are expected to begin stocking the Dr. Reddy's generic in the coming weeks, with provincial drug plans updating their reimbursement policies as the product enters distribution. Health Canada's review of the eight remaining applications continues, and at least two more approvals are expected before the end of the year if pending dossiers meet regulatory standards.

The federal government has signalled it will use the development as part of a broader push to position Canada as a country where generic and biosimilar uptake is competitive with international peers. Patent reform, drug pricing rules and the future of the Patented Medicine Prices Review Board remain on the policy table for 2026, with implications for future first-to-G7 generic approvals.

The approval is also expected to refocus attention on the broader Canadian pharmaceutical industry policy debate, including questions about domestic manufacturing capacity, supply chain resilience and the conditions necessary to attract additional generic and biosimilar production in Canada. Federal industry minister Mélanie Joly has previously signalled interest in policy levers that would encourage the establishment of more pharmaceutical manufacturing inside Canada, although the implementation pathway remains under development.

For now, though, the approval offers a tangible first step toward easing one of the most significant prescription drug cost pressures Canadian patients have faced in recent years. The size and speed of the price decline will depend on how rapidly the additional generics reach the market and how aggressively payers, providers and patients drive substitution. Canadian patients, doctors and pharmacists will be the ultimate test of whether a regulatory milestone translates into real-world affordability gains.

The pharmacist's role

Pharmacists across Canada have been preparing for the introduction of generic semaglutide for months, with continuing-education programmes covering the technical and counselling considerations specific to GLP-1 medications. Pharmacists frequently serve as the first point of contact for patients with questions about medication switching, side effects and dosing, and their role in the rollout will be significant.

Most provinces allow pharmacists to substitute generic for brand-name medications under specific conditions, although prescribing physicians can override substitution by indicating no substitution on the prescription. The interaction between pharmacist autonomy, physician preferences and patient choice will shape early uptake of the new product. Patient education materials are being developed by the Canadian Pharmacists Association to support informed decisions at the counter.

The supply chain considerations

The Dr. Reddy's product is manufactured in India, raising some discussion about supply chain dependency for an increasingly important class of medications. Canada's pharmaceutical supply chain has experienced shortages of various products in recent years, often tied to manufacturing concentration in a small number of overseas facilities.

Federal officials have indicated that supply chain resilience is one of the considerations in the broader pharmaceutical strategy review under way at Innovation, Science and Economic Development Canada. The strategy aims to identify opportunities to attract additional pharmaceutical manufacturing to Canada, particularly for essential medicines and high-volume generics.

The Ozempic generic approval is unlikely to face supply constraints in the short term, given Dr. Reddy's manufacturing capacity and the scale of Indian generic production. But longer-term considerations about supply chain diversification will continue to shape Canadian policy in this space.